Fortress Biotech Inc
FBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$146.5M
Close$
$-3.09
214.1% downside
Current Fair Value
214.1% downsideOvervalued by 214.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $146.50 Million |
|---|---|
| Enterprise Value | $8.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.07 |
| Beta | 1.21 |
| Outstanding Shares | 31,666,585 |
Return
| Return on Equity | 64.01% |
|---|---|
| Return on Assets | 33.17% |
| Return on Invested Capital | -15.70% |
Valuation & Multiples
| P/E Ratio | 0.85 |
|---|---|
| PEG | -0.82 |
| Price to Sales | 1.36 |
| Price to Book Ratio | 0.45 |
| Enterprise Value to Revenue | 0.12 |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 6.95 |
| Debt to Equity | 0.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$19.41 M
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$21.57 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 29.9508▲ 2041.08% |
|---|---|
| Total Calls | 12,200▼ 77.28% |
| Total Puts | 365,400▼ 28.67% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.99%▼ 3.76% |
|---|---|
| Total Invested | $14.95M▼ 29.52% |
| Investors Holding | 570% |
ESG Score
No data
About Fortress Biotech Inc
111 employees
CEO: Lindsay Rosenwald